Rofecoxib was recently found to greatly increase plasma concentrations of the CYP1A2 substrate drug tizanidine in humans, but there are no published in vitro studies on the CYP1A2-inhibiting effects of rofecoxib. Our objective was to investigate whether rofecoxib is a direct-acting or metabolism-dependent inhibitor of CYP1A2 in vitro. The effect of rofecoxib on the O-deethylation of phenacetin (20 M) was studied using human liver microsomes. The effect of preincubation time on the inhibitory potential of rofecoxib was also studied, and the inhibitor concentration that supports half the maximal rate of inactivation (K I ) and the maximal rate of inactivation (k inact ) were determined. Rofecoxib is a cyclooxygenase-2-selective nonsteroidal anti-inflammatory drug, which was recently withdrawn, possibly temporarily, from clinical use because of its cardiovascular side effects. Previous studies have shown that rofecoxib moderately increases plasma concentrations and effects of theophylline (Bachmann et al., 2003) and the R-isomer of warfarin (Schwartz et al., 2000) . Quite recently, rofecoxib in therapeutic doses of 25 mg per day was found to increase more than 10-fold the plasma concentrations of the CYP1A2 substrate tizanidine in humans (Backman et al., 2006b ). The effects on tizanidine pharmacokinetics suggest that rofecoxib can be a relatively potent inhibitor of CYP1A2. However, hitherto, there have been no published in vitro studies on the effect of rofecoxib on CYP1A2 activity, nor has the type of CYP1A2 inhibition by rofecoxib been clarified.
Rofecoxib is a cyclooxygenase-2-selective nonsteroidal anti-inflammatory drug, which was recently withdrawn, possibly temporarily, from clinical use because of its cardiovascular side effects. Previous studies have shown that rofecoxib moderately increases plasma concentrations and effects of theophylline (Bachmann et al., 2003) and the R-isomer of warfarin (Schwartz et al., 2000) . Quite recently, rofecoxib in therapeutic doses of 25 mg per day was found to increase more than 10-fold the plasma concentrations of the CYP1A2 substrate tizanidine in humans (Backman et al., 2006b ). The effects on tizanidine pharmacokinetics suggest that rofecoxib can be a relatively potent inhibitor of CYP1A2. However, hitherto, there have been no published in vitro studies on the effect of rofecoxib on CYP1A2 activity, nor has the type of CYP1A2 inhibition by rofecoxib been clarified.
Rofecoxib itself is extensively metabolized via complex oxidative, reductive, and back-reduction pathways ( Fig. 1) (Merck & Co., 2002; Slaughter et al., 2003) . In human liver microsomal incubations, rofecoxib has been found to be metabolized to 5-hydroxyrofecoxib by several P450 enzymes, CYP1A2 and CYP3A4 having the greatest contributions . In liver S9 fractions, the metabolite profile of rofecoxib has been more complex, including the formation of both 5-hydroxyrofecoxib and different 3,4-dihydrohydroxy acid derivatives; the latter are considered to represent the major pathways in vivo (Halpin et al., 2002) . Thus, it has been suggested that P450 enzymes play a minor role in rofecoxib's metabolism. However, in our recent study, the plasma concentrations of rofecoxib correlated to the plasma caffeine-paraxanthine ratio in vivo, suggesting a role for CYP1A2 in the metabolism of rofecoxib (Backman et al., 2006b ). Our purpose, in the current study, was to explore in vitro the CYP1A2-inhibitory potency of rofecoxib and to elucidate the type of possible CYP1A2 inhibition.
Materials and Methods

Chemicals and Microsomes. Rofecoxib (Sequoia Research Products
Limited, Pangbourne, UK), phenacetin, acetaminophen, ␤-NADPH (SigmaAldrich, St. Louis, MO), methanol, acetonitrile, and ethyl acetate (Rathburn Chemicals Ltd., Walkerburn, Scotland) were used in this study. Other chemicals were obtained from Merck (Darmstadt, Germany) . Pooled human liver microsomes were obtained from BD Gentest (Woburn, MA). Human liver tissue had been collected in accordance with all pertinent regulations.
Incubation Conditions. Phenacetin O-deethylation (acetaminophen formation) was used as an index reaction for CYP1A2 activity (Distlerath et al., 1985; Tassaneeyakul et al., 1993) . All incubations were performed in duplicate (all the data were within 12% of their mean) in a shaking water bath at 37°C. The incubations were carried out in 0.1 M sodium phosphate buffer (pH 7.4), containing 5.0 mM MgCl 2 , 1.0 mM ␤-NADPH, 20 M phenacetin, and human liver microsomes (0.1 mg ml Ϫ1 protein) in a total volume of 1000 l. The incubation mixture components, except ␤-NADPH, were premixed and the resulting mixture was kept at room temperature for 3 min, and incubations were begun by addition of ␤-NADPH. Aliquots of 200 l were removed at 20 min, and the reactions were stopped with 100 l of acetonitrile including the internal standard, hydrochlorothiazide, and cooling on ice. To evaluate the inhibitory effect of rofecoxib on CYP1A2 activity, various concentrations of rofecoxib were added to the incubation mixture before addition of ␤-NADPH. Rofecoxib was dissolved in acetonitrile, and phenacetin in methanol, the final solvent concentration not exceeding 1%.
To evaluate the potential of metabolism-dependent inhibition by rofecoxib, incubation mixtures were prepared as described earlier, but without the substrate. Preincubations were started by addition of ␤-NADPH. At 30 min, phenacetin was added to the mixtures and the incubations were allowed to proceed for 20 min. To determine the K I (the inhibitor concentration needed to cause half-maximal rate of inactivation) and k inact (the maximal rate of inactivation with saturable concentration of the inhibitor), the preincubation mixture was prepared as described above, except that a microsomal protein concentration of 1 mg ml Ϫ1 was used. Rofecoxib concentrations of 1 to 48 M were used. The mixture was preincubated for 0 to 25 min, and an aliquot of 100 l was then transferred to another incubation tube containing phenacetin (20 M) and ␤-NADPH, in a final volume 1000 l, to determine residual CYP1A2 activity. Thus, rofecoxib was diluted to one-tenth of its original concentration, so that in the final incubation mixture, the "direct" inhibition of CYP1A2 by the highest rofecoxib concentration would not exceed 25%.
To determine the effect of trapping agents and an alternative competitive inhibitor on CYP1A2 inactivation, the preincubation mixture was prepared as in k inact and K I determinations. Preincubations were carried out with or without glutathione (2 mM), superoxide dismutase (1000 U/ml), mannitol (1 mM), and fluvoxamine (0.01, 0.1, and 1 M) both in the absence (control) and presence of 12 M rofecoxib. The mixture was preincubated for 30 min; an aliquot of 100 l was transferred to another incubation tube (final volume of 1000 l), and the residual phenacetin O-deethylation activity was measured as described above.
To evaluate the effect of dialysis on the inhibitory effect of rofecoxib, human liver microsomes were preincubated with or without 12 M rofecoxib for 30 min as described earlier (1 mg ml Ϫ1 microsomal protein). The samples were immediately dialyzed against 0.1 M sodium phosphate buffer (pH 7.4) containing 1% solvent (three times for 2 h in a volume of 2 liters) at 4°C, followed by a 10-fold dilution and measurement of phenacetin O-deethylation activity as described above.
Measurement of Drug Concentrations. Acetaminophen and its internal standard, hydrochlorothiazide, were extracted with 5.0 ml of ethyl acetate. After centrifugation, the supernatant was evaporated to dryness under nitrogen, and the residue was reconstituted with 100 l of the mobile phase (6 mM ammonium acetate, pH 9.0/acetonitrile, 78:22). Thereafter, acetaminophen concentration was determined by high-performance liquid chromatography with UV detection (230 nm A Hewlett-Packard 1100 system (Hewlett-Packard, Waldbrunn, Germany) and a Waters Symmetry C8 reversed-phase column, 4.6 ϫ 150 mm (Waters, Milford, MA) were used. The limit of quantification for acetaminophen was 10 nM.
The nonspecific binding of 1 M and 12 M rofecoxib to the microsomes (1 mg/ml microsomal protein) was determined with equilibrium dialysis for 18 h at 37°C. Rofecoxib and its internal standard, etoricoxib, were extracted with 5.0 ml of methyl-tert-butyl ether. After centrifugation, the supernatants were evaporated to dryness under nitrogen, and the residues were reconstituted with 100 l of the mobile phase (acetonitrile/water, 45:55). Rofecoxib concentrations were determined by high-performance liquid chromatography with UV detection (270 nm) . The limit of quantification for rofecoxib was 20 nM.
Data Analysis. The IC 50 values were determined by nonlinear regression analysis with SigmaPlot 8.0 (SPSS Inc., Chicago, IL). For estimation of inactivation constants, preincubation time-dependent loss of CYP1A2 activity in the absence of rofecoxib was accounted for by adjusting the observed rate of metabolism with reference to the respective (vehicle) control incubation at each preincubation time. The initial rate constant of inactivation of CYP1A2 activity by each inhibitor concentration (K obs ) was determined by linear regression analysis of the natural logarithm of the percentage of activity remaining versus preincubation time data (Kitz and Wilson, 1962) . Thereafter, the K obs values were used to determine the inhibitor concentration needed to cause a half-maximal rate of enzyme inactivation (K I ) and the maximal rate of inactivation (k inact ). Initial estimates of K I and k inact were obtained from a double-reciprocal plot of the K obs (y-axis) versus inhibitor concentration [I] (x-axis) (Kitz and Wilson, 1962) . When extrapolated over the axes, the reciprocal of the intercept of the y-axis gives k inact , and the negative reciprocal of the intercept of the x-axis gives K I . Then, the K I and k inact were estimated by nonlinear regression using the following equation (Jones et al., 1999) :
In Vivo Simulations. In vitro data describing mechanism-based inhibition (the k inact /K I ratio) can be used to evaluate the potential clinical impact of the inhibition according to the following equation :
FIG. 1. Metabolic pathways of rofecoxib in vitro .
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where AUC po(i) is the area under the concentration-time curve of the substrate during inactivation of the enzyme caused by the inhibitor, AUC po(c) is the control value, f m ⅐ f m,P450 represents the fraction of the substrate dose cleared by the P450 enzyme, and k e is the rate constant for enzyme degradation in the absence of the inhibitor. In a previous study, k e estimates ranging from 0.0005 to 0.00026 min Ϫ1 yielded the most accurate in vivo predictions of CYP1A2 inhibition by the mechanism-based inhibitor zileuton . In our simulations, a CYP1A2 half-life of 38.6 h (i.e., k e ϭ 0.0003 min Ϫ1 ) was assumed, based on a previous estimate of the in vivo CYP1A2 half-life (Faber and Fuhr, 2004; Ghanbari et al., 2006) . This value is similar to the in vitro half-life estimate of 36 h determined for CYP1A2 in liver slices (Renwick et al., 2000) . It should be noted that the equation used assumes that the substrate is completely absorbed from the gastrointestinal tract, its hepatic clearance can be described by the well stirred pharmacokinetic model, the substrate is metabolized in the liver only, its pharmacokinetics are linear, and the inhibitor does not affect its absorption or clearance by other mechanisms.
Results
Effect of Rofecoxib on CYP1A2 Activity. Rofecoxib inhibited CYP1A2 activity with an IC 50 value of 23.0 M in human liver microsomes, when no preincubation was carried out (Fig. 2) . A 30-min preincubation of rofecoxib in the presence of ␤-NADPH increased the inhibition of CYP1A2 considerably (Fig. 2) , suggesting that rofecoxib is a metabolism-dependent inhibitor of CYP1A2. The IC 50 value of rofecoxib with the preincubation was 4.18 M. This preincubation-dependent inactivation of CYP1A2 required ␤-NADPH (data not shown).
Inactivation of CYP1A2 by Rofecoxib. The inhibition of CYP1A2 activity by rofecoxib was preincubation time-and concentration-dependent (Fig. 3) . The inactivation variables K I and k inact for CYP1A2 were 4.78 M and 0.070 min Ϫ1 , respectively, when determined with the nonlinear regression method (Fig. 3) . The k inact value implies that 7% of CYP1A2 is inactivated each minute when a saturating concentration of rofecoxib is incubated with human liver microsomes. The partition ratio (number of molecules metabolized via noninactivating pathways per one inactivating event), estimated as described previously (Kunze and Trager, 1993) and assuming a CYP1A2 proportion of approximately 20% (Klein et al., 2006) , was approximately 3. The nonspecific binding of rofecoxib to microsomes was less than 5% (data not shown).
Superoxide dismutase, glutathione, and mannitol had no significant effect on CYP1A2 inactivation caused by rofecoxib, and dialysis could not restore CYP1A2 activity (Table 1) . Fluvoxamine diminished the rofecoxib-induced inactivation of the enzyme in a concentration-dependent manner (Table 1 ). For example, 1.0 M fluvoxamine decreased the inactivation caused by 12 M rofecoxib from 63% to 6%. (Fig. 4) . When a clinically relevant total plasma rofecoxib concentration of 1 M, and the K I of 4.78 M and the k inact of 0.070 min Ϫ1 of rofecoxib were used in simulations, marked (Ͼ3-fold) increases in the AUC of compounds extensively (Ͼ70%) metabolized by CYP1A2 were predicted. The unbound mean peak plasma concentration of rofecoxib, 150 nM after a 25-mg daily dose, assuming an 85% protein binding in plasma (Merck &Co., 2002) , was predicted to cause an approximately 8-fold increase in the AUC of a drug for which f m ⅐ f m,CYP1A2 is 0.98. The corresponding predicted increase in the AUC was 2.6-fold for a drug with a f m ⅐ f m,CYP1A2 of 0.70, but only 1.54-fold for a drug with a f m ⅐ f m,CYP1A2 of 0.40.
Discussion
In previous pharmacokinetic studies, rofecoxib has moderately increased the plasma concentrations of R-warfarin and theophylline (Schwartz et al., 2000; Bachmann et al., 2003) , and greatly increased the plasma concentrations of tizanidine (Backman et al., 2006b ). In the present in vitro study, we wanted to elucidate the mechanism of these interactions by studying the effect of rofecoxib on CYP1A2 activity (phenacetin O-deethylation) in human liver microsomes. Our findings are consistent with a potent mechanism-based inhibition of CYP1A2 by rofecoxib, thus providing a likely mechanistic explanation for the interactions.
Rofecoxib inhibited CYP1A2 with an IC 50 value of 23.0 M without preincubation. However, typical total plasma concentrations of rofecoxib are less than 10% of this IC 50 value. Therefore, direct inhibition of CYP1A2 is unlikely to explain the strong interaction with tizanidine in humans (Bachmann, 2006) . Preincubation of rofecoxib in the presence of NADPH considerably increased its inhibitory effect. This inactivation of CYP1A2 was dependent on preincubation time, rofecoxib concentration, and NADPH, indicating that the inactivation proceeded via catalytic step(s). The decrease in inactivation observed in the presence of increasing concentrations of the competitive CYP1A2 inhibitor, fluvoxamine, and the lack of effect of glutathione, superoxide dismutase, and mannitol, suggest that the inactivating metabolite is formed at the CYP1A2 active site and does not leave the active site before the inactivation takes place. These findings are consistent with criteria for mechanism-based inhibition (Silverman, 1995) .
In an additional experiment, the K I and k inact values of rofecoxib for CYP1A2 were 4.8 M and 0.070 min Ϫ1 . Prediction of in vivo interactions on the basis of these values (Fig. 4) , and the free C max of rofecoxib, 0.15 M with 25 mg of rofecoxib daily (Merck & Co., 2002; Backman et al., 2006b) , conformed fairly well, but not exactly, with the findings of the pharmacokinetic studies with tizanidine, theophylline, and R-warfarin (Schwartz et al., 2000; Bachmann et al., 2003; Backman et al., 2006b) . The fraction of the substrate metabolized by CYP1A2 (f m ⅐ f m,CYP1A2 ) is crucial for in vitro-in vivo extrapolations. The f m ⅐ f m,CYP1A2 values for tizanidine, theophylline, and R-warfarin are approximately 0.98, 0.7, and Յ0.4, respectively (Kaminsky and Zhang, 1997; Rasmussen et al., 1997; Yao et al., 2001; Granfors et al., 2004b; Backman et al., 2006a) . In the in vivo studies with healthy volunteers, rofecoxib (25 mg daily) has raised the AUC of tizanidine, theophylline and R-warfarin 13.6-fold, 1.51-fold, and 1.38-fold, respectively (Schwartz et al., 2000; Bachmann et al., 2003; Backman et al., 2006b ). Thus, our predictions seem to slightly underestimate the interaction with tizanidine (8-fold predicted increase in AUC), and overestimate the interactions with theophylline (2.6-fold predicted increase) and R-warfarin (1.54-fold predicted increase).
It is possible that the f m ⅐ f m,CYP1A2 values of tizanidine, theophylline, and R-warfarin in the healthy volunteer studies differed from our estimates, partially explaining this apparent slight discrepancy in the predictions. However, a more likely explanation is that rofecoxib affected mainly the first-pass metabolism of the high-clearance drug tizanidine, whereas it affected the metabolism of the low-clearance drugs theophylline and R-warfarin exclusively during their elimination phase. Thus, the plasma concentration of rofecoxib at the time of tizanidine absorption may largely determine the extent of interaction with tizanidine. On the other hand, the mean or trough concentrations of rofecoxib (approximately 50 -70% lower than the C max ) may be a more important determinant for interactions with drugs that do not have significant first-pass metabolism, like theophylline and warfarin. Moreover, it is obvious that the C max of rofecoxib in the portal vein dmd.aspetjournals.org is higher than its C max in peripheral blood, further facilitating the inactivation of CYP1A2 during the absorption of rofecoxib. The free rofecoxib C max in portal vein can be estimated from the following equation:
where f u is the unbound fraction (15%), D is the dose (25 mg), F a is the oral bioavailability (93%), k a is the absorption rate constant, and Q h is the hepatic blood flow (1500 ml min Ϫ1 ) (Merck & Co., 2002) . Since the peak concentration of rofecoxib can occur at 2 h and its half-life averages 20 h (Merck & Co., 2002; Backman et al., 2006b ), the k a of rofecoxib can be estimated to approximate 0.035 min Ϫ1 . Thus, according to eq. 3, the C max, portal, free of rofecoxib could be approximately 400 nM, i.e., 2.7 times higher than the free C max in peripheral blood. This would yield a prediction of a 14.8-fold increase in the AUC of a drug with a f m ⅐ f m,CYP1A2 of 0.98.
The molecular structure of rofecoxib includes a furanone ring, which is the site of its CYP1A2-mediated oxidation to 5-hydroxyrofecoxib (Fig. 1) , and a possible structure involved in the observed inactivation of CYP1A2. A furan ring, which lacks the ketone group of the furanone ring, is one of the most common substructures causing mechanism-based inhibition (Fontana et al., 2005) . It has been suggested that the mechanism includes the formation of an epoxide intermediate, which can be nucleophilically attacked by a nitrogen atom of a protein side chain or a heme, leading to a covalent binding between the inhibitor and the P450 enzyme. However, metabolism of the furan ring of furafylline has been questioned as a basis for CYP1A2 inactivation (Racha et al., 1998) . It is interesting that the spontaneous formation of a reactive maleic anhydride, which binds covalently to elastin fibers, has been suggested to be involved in the cardiovascular toxicity of rofecoxib (Reddy and Corey, 2005) .
CYP1A2 is one the major hepatic drug-metabolizing P450 enzymes. It is largely responsible for the metabolism of many important xenobiotics including caffeine, theophylline, clozapine, olanzapine, duloxetine, tacrine, riluzole, lidocaine, zolmitriptan, and tizanidine (Berthou et al., 1991; Bertilsson et al., 1994; Ha et al., 1995; Madden et al., 1995; Ring et al., 1996; Wang et al., 2000; Granfors et al., 2004a) and is partially involved in the metabolism of, for example, tricyclic antidepressants and the Risomer of warfarin Kaminsky and Zhang, 1997; Olesen and Linnet, 1997) . In addition, CYP1A2 plays a central role in the metabolism of certain endogenous compounds such as melatonin, 17␤-estradiol, and uroporphyrinogen (Aoyama et al., 1990; Lambrecht et al., 1992; Facciola et al., 2001) . Some animal data suggest that CYP1A2 can have important housekeeping functions, in addition to its role in drug metabolism (Smith et al., 2003) .
Rofecoxib has previously been suggested to have a relatively low propensity to interact with drugs metabolized by P450 enzymes (Merck & Co., 2002; Slaughter et al., 2003) . However, the inhibition of CYP1A2 by rofecoxib is clinically relevant as documented by the clinical studies with tizanidine, theophylline, and warfarin (Schwartz et al., 2000; Bachmann et al., 2003; Backman et al., 2006b) . It is likely that the metabolism of other CYP1A2 substrate drugs also is markedly inhibited by rofecoxib. This inhibition is likely to be particularly important when the victim drug has a low non-CYP1A2-mediated clearance and a small therapeutic range, like, for example, clozapine. It is also possible that rofecoxib can affect the CYP1A2-mediated metabolism of dietary and endogenous compounds, such as caffeine and estrogens, which might explain some of the adverse effects of rofecoxib. Rofecoxib has inhibited the metabolism of caffeine in healthy volunteers (Backman et al., 2006b) , and according to recent findings, intake of caffeine may be associated with an increased risk of myocardial infarction among individuals with "slow caffeine metabolism" (Cornelis et al., 2006) .
In our recent in vivo study, the AUC of rofecoxib correlated significantly with the caffeine/paraxanthine ratio (Backman et al., 2006b) , suggesting that CYP1A2 has a significant role in the metabolism of rofecoxib. However, rofecoxib is mainly reduced to different 3,4-dihydrohydroxy acid derivatives in vivo (Fig. 1) , and P450 enzymes have been suggested to play only a minor role in its metabolism (Merck & Co., 2002; Slaughter et al., 2003) . In vitro, CYP1A2 and CYP3A4 have catalyzed the 5-hydroxylation of rofecoxib, but the contributions of non-P450-mediated pathways to the total metabolism of rofecoxib have been greater .
The concentrations of rofecoxib used in the above-mentioned in vitro study were 10 M and 60 M, and the incubation time was 15 min. These concentrations are approximately 100 times higher than the unbound concentrations of rofecoxib in plasma with typical clinical dosing. Such high concentrations can rapidly inactivate CYP1A2 (K I 4.8 M, k inact 7% per minute). Therefore, the previous in vitro studies may have underestimated the contribution of CYP1A2 to the metabolism of rofecoxib. Another factor potentially leading to underestimation of the role of P450 enzymes is the NADPH-dependent back-reduction of 5-hydroxyrofecoxib to rofecoxib in vitro . Accordingly, it is possible that CYP1A2 contributes to the metabolism of rofecoxib in vivo. Thus, autoinhibition of the CYP1A2-mediated metabolism of rofecoxib could also explain its nonlinear pharmacokinetics in vivo (Merck & Co., 2002; Bachmann et al., 2003) . Moreover, autoinhibition can be a pitfall leading to erroneous conclusions when the metabolism of a drug is studied in vitro using concentrations much higher than its free plasma concentrations in humans in vivo.
In conclusion, rofecoxib is a potent, metabolism-dependent inhibitor of CYP1A2. It also seems that the role of CYP1A2 in the metabolism of rofecoxib itself is greater than what has been recognized previously. The results provide a mechanistic explanation for the interactions of rofecoxib with CYP1A2 substrates and, possibly, for its nonlinear pharmacokinetics.
